Pharma BD Deal Intelligence
A cheap option that Sanofi kept exercising: $17.5M upfront for Adagene's SAFEbody platform grew into a third discovery program and up to $25M in equity by 2025, backing muzastotug — but the $2.5B in milestones remains almost entirely unearned.
Outcome grade pending — assessed 5 years post-close.
Full analysis, sources & comparables →Sanofi has agreed to pay Adagene up to $2.5 billion in a collaboration covering up to four immuno-oncology candidates using the biotech's SAFEbody…
Sanofi announced a global collaboration and exclusive license agreement with Adagene to develop novel masked monoclonal and bispecific antibody candidates…
Adagene announces up to US$25M strategic investment from Sanofi; Sanofi exercises option for a third SAFEbody discovery program (bispecific, undisclosed…
Source summaries from our enrichment pipeline; follow links for originals.
All 12 sources with sentiment breakdown →
Adagene and Sanofi entered a collaboration and exclusive license agreement to generate masked monoclonal and bispecific antibodies using Adagene's SAFEbody conditional-activation technology. Sanofi paid $17.5M upfront and could advance two initial candidates with options for two more; Adagene is eligible for up to $2.5B in milestones plus tiered royalties. The alliance has since expanded: in July 2025 Sanofi exercised its option to select a third SAFEbody discovery program (a bispecific with undisclosed targets), triggering an option exercise fee, milestones and royalties per the 2022 agreement, and made a strategic equity investment of up to $25M in Adagene ($17.0M at first close plus $8.0M contingent on Full Phase 2 Enrollment), with Sanofi also supporting clinical development of Adagene's anti-CTLA-4 SAFEbody muzastotug (ADG126).
600K US cases/yr · $138.0B Global immuno-oncology market forecast (2030) · 2517 Total Sanofi-Adagene SAFEbody deal value (USD MM upfront + milestones)
The Sanofi-Adagene SAFEbody collaboration targets oncology indications addressable by conditionally activated (masked) monoclonal and bispecific antibodies. The platform is most relevant for tumors where validated immune-oncology targets — including PD-1/PD-L1, CTLA-4, CD3, CD47, TIGIT, LAG-3 and emerging tumor-associated antigens — carry meaningful on-target/off-tumor toxicity that has limited dosing or constrained combination utility. Approximately 1.9 million new US cancer cases are diagnosed annually (ACS 2024), with roughly 600,000 advanced/metastatic patients per year representing the addressable IO population. Approximately 30-40% of solid-tumor patients respond to first-generation checkpoint inhibitors, leaving the majority as primary or acquired non-responders where combination IO regimens are actively being developed but limited by additive toxicity. Masked-antibody platforms (CytomX's Probody, Adagene's SAFEbody, Maverick's COBRA, Janux's TRACTr, Werewolf's INDUKINE) aim to restrict antibody activation to the tumor microenvironment via protease-cleavable masking peptides, broadening the therapeutic index of high-affinity targets like CD3 bispecifics and CD47 antagonists. Global immuno-oncology market was approximately $64B in 2023 and is forecast to reach $138B by 2030.
Conditionally activated antibody platforms have emerged as a defined competitive class with multiple major-pharma partnership validations. Adagene's SAFEbody competes most directly with CytomX Therapeutics' Probody platform (Bristol Myers Squibb partnership for vopratelimab/CX-072 PD-L1 Probody and BMS-986288 CTLA-4 Probody) and was previously partnered by AbbVie. Other masked-antibody and conditional-activation platforms: Janux Therapeutics' TRACTr (Merck partnership across multiple T-cell engagers), Maverick Therapeutics' COBRA (acquired by Takeda 2021), Werewolf Therapeutics' INDUKINE (Jazz partnership), Harpoon Therapeutics' ProTriTAC (Merck partnership for HPN217 and HPN601), Amunix's Pro-XTEN (Sanofi acquisition 2021 — overlaps strategic rationale with Adagene deal), and Asher Biotherapeutics' targeted cytokine masking. Approved or pivotal IO benchmarks shaping the unmet need: Keytruda (pembrolizumab, Merck, ~$25B 2023), Opdivo (nivolumab, BMS, ~$9B), Yervoy (ipilimumab, BMS), Tecentriq (atezolizumab, Roche), Imfinzi (durvalumab, AZ), Libtayo (cemiplimab, Regeneron), Opdualag (nivolumab plus relatlimab, BMS LAG-3 combo). CD3 bispecific platforms benefiting most from masking: Tecvayli (teclistamab, J&J), Talvey (talquetamab, J&J), Elrexfio (elranatamab, Pfizer), Tarlatamab (Imdelltra, Amgen). Sanofi's $1B+ Amunix acquisition in late 2021 plus this Adagene collaboration signal an explicit strategy to build a masked-antibody capability stack.
Sanofi exercised its option to select a third SAFEbody discovery program under the 2022 collaboration -- a bispecific therapeutic with undisclosed targets -- triggering an option exercise fee plus milestones and royalties per the 2022 agreement.
Sanofi committed up to US$25M strategic equity investment in Adagene: $17.0M at first closing (2025-07-02) plus $8.0M contingent on Adagene achieving Full Phase 2 Enrollment of muzastotug (ADG126).
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Sanofi SA / Adagene Inc. (this deal) | 2022 | $2.5B | — |
| Sanofi SA / Regeneron Pharmaceuticals, Inc. | 2007 | $1.0B | 97 |
| Sanofi SA / Synthelabo S.A. | 1998 | $11.0B | 84 |
| Sanofi SA / Genzyme Corporation | 2011 | $20.1B | 84 |
| Sanofi SA / Amunix Pharmaceuticals Inc. | 2021 | $1.2B | 76 |
| Sanofi SA / Genzyme Corporation | 2010 | $18.5B | 75 |
| Sanofi SA / Translate Bio Inc. | 2018 | $805M | 73 |
← Browse all deals · How we score deals
More: 2022 deals · Sanofi SA deals · Oncology deals